Vizient, Inc. is pleased to participate in the Food and Drug Administration's (FDA) 2024 Compounding Quality Center of Excellence Annual Conference, taking place August 21-23. This year’s conference, themed “Learning and Collaborating: Driving Toward the Future of Quality,” will be hosted in a hybrid format.

The conference offers a platform for outsourcing facilities and industry professionals to learn, network, and enhance the quality of compounded drugs for patients in need. Highlights include in-depth sessions on quality, current good manufacturing practice requirements, and building future partnerships, along with networking opportunities and educational sessions with FDA and industry leaders.

On Wednesday, August 21 from 2:30-3:30 p.m. ET, Jenna Stern, associate vice president of regulatory affairs and public policy, will moderate a panel discussion titled “The Business Case for Quality and Resilience,” which will explore different perspectives regarding quality and resilience. The panel will feature a range of experts, including those from outsourcing facilities and hospitals.

“We thank the FDA for including Vizient in these vital discussions, which are important to bridge gaps and bolster communication between outsourcing facilities and hospitals and health systems,” said Stern. “At Vizient, maintaining strong collaboration with the FDA and industry partners is a priority, as we continue to support our providers with the resources to access compounded medications.”

The FDA Compounding Quality Center of Excellence was established to proactively support outsourcing facilities and market stakeholders in delivering quality prescription drugs to patients in need. In addition to facilitating training and market research, the Center engages industry partners through its annual conference to promote the quality of compounded drugs.

Learn more about Vizient's Pharmacy Solutions and advocacy to support providers.

About Vizient, Inc.

Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents $140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240820121023/en/